Light chain amyloidosis: the heart of the problem
- 1 October 2013
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 98 (10) , 1492-1495
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicityBasic Research in Cardiology, 2013
- Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafishAmerican Journal of Physiology-Heart and Circulatory Physiology, 2013
- Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvementHaematologica, 2013
- Left ventricular device implantation for advanced cardiac amyloidosisThe Journal of Heart and Lung Transplantation, 2013
- CyBorD: stellar response rates in AL amyloidosisBlood, 2012
- Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosisBlood, 2011
- Amyloidosis: Pathogenesis and New Therapeutic OptionsJournal of Clinical Oncology, 2011
- Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvementBlood, 2010
- Serum N-Terminal Pro–Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL AmyloidosisCirculation, 2003
- Infusion of Light Chains From Patients With Cardiac Amyloidosis Causes Diastolic Dysfunction in Isolated Mouse HeartsCirculation, 2001